In 1,071 women diagnosed at 40 or younger, lower income was tied to delayed presentation and younger age to delayed diagnosis.
|Articles|August 8, 2014
Dr. Wojciechowski Discusses New Research in Breast Cancer
In this podcast, Brian Wojciechowski, MD, Breastcancer.org medical adviser, discusses some of the research that was published in July 2014.
Advertisement
In this podcast, Brian Wojciechowski, M.D., Breastcancer.org medical adviser, discusses some of the research that was published in July 2014. Listen to the podcast to hear Dr. Wojciechowski talk about:
- why treating inflammatory breast cancer with three treatments -- chemotherapy, surgery, and radiation -- improves survival compared to using only one or two of these treatments
- the reasons why having more moles is linked to a higher risk of breast cancer, though moles themselves DO NOT cause breast cancer
- research showing that women with an abnormal BRCA1 gene -- but not an abnormal BRCA2 gene -- diagnosed with breast cancer are more likely to survive if they have their ovaries and fallopian tubes removed
- a study that found combining 3-D mammograms (digital tomosynthesis) and digital mammograms find more breast cancers with fewer false positives
Click Here to Listen
Running time: 20:50
Advertisement
Related to this article
A Columbia nurse scientist shares her takeaways from the 2026 ASCO Quality Care Symposium, from geriatric assessment to care across the age span.
A patient, a caregiver, nurses, an NP, and an oncologist discuss rash prevention, dose holds, cost, and trial eligibility with oral daraxonrasib.
Daisy Molina, EdD, MSN, RNC-LRN, explains how nurses can include caregivers in breast cancer care while keeping the patient's voice central.
In a 117-patient cohort, 35% waited over 60 days for neoadjuvant chemotherapy, most often because of added workup, second opinions or comorbidities.
Interviews with 15 young women with breast cancer show fertility preservation decisions unfold under time pressure and carry into survivorship.
FDA grants accelerated approval to amivantamab and hyaluronidase-lpuj for recurrent or metastatic head and neck squamous cell carcinoma.
Lisa Carter-Bawa, PhD, MPH, APRN, explains how nurses can counter lung cancer fatalism by pairing honesty with hope and using teach-back.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Patients, Nurses Share What Daraxonrasib Means in Practice
2
ASCO Quality Care 2026: Closing the Gap Between Evidence and Practice
3
For Young Women With Cancer, Fertility Choices Evolve Beyond Diagnosis
4
FDA Approves Amivantamab for Recurrent or Metastatic HNSCC
5